Mega Lifesciences Public Company Limited (MEGA-R) - Total Assets
Based on the latest financial reports, Mega Lifesciences Public Company Limited (MEGA-R) holds total assets worth ฿14.31 Billion THB (≈ $446.11 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Mega Lifesciences Public Company Limited - Total Assets Trend (2010–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's total assets have evolved over time, based on quarterly financial data. Also see MEGA-R company net worth for the company's overall valuation and market capitalisation.
Mega Lifesciences Public Company Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Mega Lifesciences Public Company Limited's total assets of ฿14.31 Billion consist of 72.0% current assets and 28.0% non-current assets. Review debt load of Mega Lifesciences Public Company Limited to assess the company's total debt and financial obligations.
| Asset Category | Amount (THB) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ฿0.00 | 24.4% |
| Accounts Receivable | ฿2.98 Billion | 20.9% |
| Inventory | ฿3.03 Billion | 21.3% |
| Property, Plant & Equipment | ฿0.00 | 0.0% |
| Intangible Assets | ฿869.72 Million | 6.1% |
| Goodwill | ฿449.00 Million | 3.2% |
Asset Composition Trend (2010–2024)
This chart illustrates how Mega Lifesciences Public Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest Mega Lifesciences Public Company Limited stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mega Lifesciences Public Company Limited's current assets represent 72.0% of total assets in 2024, a decrease from 82.4% in 2010.
- Cash Position: Cash and equivalents constituted 24.4% of total assets in 2024, up from 4.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 0.0% in 2010.
- Asset Diversification: The largest asset category is inventory at 21.3% of total assets.
Mega Lifesciences Public Company Limited Competitors by Total Assets
Key competitors of Mega Lifesciences Public Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥29.95 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Harbin Pharmaceutical Group Co Ltd
SHG:600664
|
China | CN¥14.08 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
Mega Lifesciences Public Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.57 | 2.25 | 1.63 |
| Quick Ratio | 1.80 | 1.50 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ฿6.18 Billion | ฿5.95 Billion | ฿2.94 Billion |
Mega Lifesciences Public Company Limited - Advanced Valuation Insights
This section examines the relationship between Mega Lifesciences Public Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.71 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | ฿14.21 Billion |
| Market Capitalization | $869.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mega Lifesciences Public Company Limited's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Mega Lifesciences Public Company Limited's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Mega Lifesciences Public Company Limited (2010–2024)
The table below shows the annual total assets of Mega Lifesciences Public Company Limited from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ฿14.21 Billion ≈ $442.92 Million |
-2.13% |
| 2023-12-31 | ฿14.52 Billion ≈ $452.56 Million |
-0.87% |
| 2022-12-31 | ฿14.65 Billion ≈ $456.52 Million |
+10.36% |
| 2021-12-31 | ฿13.27 Billion ≈ $413.67 Million |
+14.51% |
| 2020-12-31 | ฿11.59 Billion ≈ $361.24 Million |
+10.04% |
| 2019-12-31 | ฿10.53 Billion ≈ $328.30 Million |
+9.34% |
| 2018-12-31 | ฿9.63 Billion ≈ $300.24 Million |
+10.47% |
| 2017-12-31 | ฿8.72 Billion ≈ $271.79 Million |
+9.81% |
| 2016-12-31 | ฿7.94 Billion ≈ $247.51 Million |
+4.31% |
| 2015-12-31 | ฿7.61 Billion ≈ $237.28 Million |
+13.24% |
| 2014-12-31 | ฿6.72 Billion ≈ $209.53 Million |
+2.85% |
| 2013-12-31 | ฿6.54 Billion ≈ $203.72 Million |
+58.05% |
| 2012-12-31 | ฿4.14 Billion ≈ $128.89 Million |
+25.70% |
| 2011-12-31 | ฿3.29 Billion ≈ $102.54 Million |
+48.14% |
| 2010-12-31 | ฿2.22 Billion ≈ $69.22 Million |
-- |
About Mega Lifesciences Public Company Limited
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provi… Read more